2 unknown. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Unknown 2 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of the Safety and Efficacy of BCMA CAR-NK Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) - Immunotherapy, Multiple Myeloma | Early Phase 1 | Unknown | Shenzhen Pregene Biopharma Co., Ltd. | 19 | 2022-11-13 | 2022-12-15 |
| Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas Nivolumab 10 MG/ML, Ablative fractionated laser - BCC - Basal Cell Carcinoma, Immune Response | Early Phase 1 | Unknown | Bispebjerg Hospital | 30 | 2020-01-27 | 2020-09-30 |
Carcinoma, Basal Cell (1) · Multiple Myeloma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Carcinoma (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms, Basal Cell (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Plasma Cell (1)
Nivolumab (1)
Bispebjerg Hospital (1) · Shenzhen Pregene Biopharma Co., Ltd. (1)
China (1) · Denmark (1)